Storing Your Patient’s Tissue

Storing living tumor tissue connects patients to NEW options

Tumor tissue usage has traditionally been used for drug discovery and basic research until recently.  SpeciCare is leading the way in bringing together individual research and precision cancer care delivery by collecting, processing and storing patients’ viable and fixed tumor tissue for all types of cancers in multiple formats including:

With our unique collection kit (SpeciKit®) we help you preserve your patient’s tissue at the time of surgery or biopsy.   We  will obtain all legal documentation from your patient to take control of his or her living tumor tissue and provide the SpeciKit® for use the day of surgery.  The kit includes easy instructions for tissue collection as well as a pre-paid postage for easy delivery back to SpeciCare.

Upon receipt of your patient’s tissue, the pathology laboratory will process the tissue to confirm percent necrosis, percent viable tumor and document the number of aliquots of viable dissociated tissue and the number of vials of chunk tissue that were successfully collected and preserved for physician and patient directed use.

We help you create new treatment opportunities and clinically actionable research information in the treatment of your patients.

 

Our unique process developed with SpeciCare takes living tissue from the patient to preserve in several formats, thereby maximizing opportunities for the specimens use for the patient’s benefit. This biological material is preserved using state-of-the art cryopreservation methods similar to those used by industry-leading biorepositories and in vitro fertilization clinics worldwide. All specimens are reviewed by ASCP-certified Cytotechnologists and Pathologists in order to determine the content and quality of preserved specimens.

We are pleased with the process that has been developed because it empowers the patient to take part in their own outcomes. By preserving cells and tissue from the patient and giving them ownership of the specimens, they become an active participant in the treatment process. We are very excited to be able to provide this service to the patient through our work with SpeciCare and hope that by increasing the availability of high-quality specimens, cancer treatment can evolve to a more informed and targeted process at the individual level.

DR. CAROL C. EISENHUT MD, MBA

President, DCL Pathology
SpeciCare Partner

CALL US Save your Tumor today
Top of Page